tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Blackham A and Griffiths RJ | The effect of FK506 and cyclosporin A on antigen-induced arthritis. | 1991 | Clin. Exp. Immunol. | pmid:1718639 |
| Carobbi A et al. | Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. | 1991 | Transplant. Proc. | pmid:1703704 |
| Fukuda T et al. | Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. | 1991 | Int. Arch. Allergy Appl. Immunol. | pmid:1718889 |
| Murase N et al. | FK 506 prevents spontaneous diabetes in the BB rat. | 1991 | Transplant. Proc. | pmid:1703705 |
| Abu-Elmagd KM et al. | Strategy of FK 506 therapy in liver transplant patients: effect of graft function. | 1991 | Transplant. Proc. | pmid:1721272 |
| Ericzon BG et al. | Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721273 |
| Jain AB et al. | Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. | 1991 | Transplant. Proc. | pmid:1721274 |
| McMichael J et al. | Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721275 |
| Donnelly JG and Soldin SJ | Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721305 |
| Rosborough SL et al. | Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. | 1991 | Transplant. Proc. | pmid:1721306 |
| Zeevi A et al. | In vitro assessment of FK 506 immunosuppressive activity in transplant patients. | 1991 | Transplant. Proc. | pmid:1721307 |
| Katz HR et al. | Mast cell biochemical and functional heterogeneity. | 1991 | Transplant. Proc. | pmid:1721308 |
| Woodle ES et al. | FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. | 1991 | Transplant. Proc. | pmid:1721337 |
| Shaw BW et al. | FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. | 1991 | Transplant. Proc. | pmid:1721338 |
| McDiarmid SV et al. | FK 506 rescue therapy in liver transplantation: outcome and complications. | 1991 | Transplant. Proc. | pmid:1721339 |
| Rucay P et al. | FK 506 rescue therapy for refractory acute rejection in five liver recipients. | 1991 | Transplant. Proc. | pmid:1721340 |
| Macleod AM and Thomson AW | FK 506: an immunosuppressant for the 1990s? | 1991 | Lancet | pmid:1702172 |
| Darras FS et al. | Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721368 |
| Shapiro R et al. | Kidney transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703352 |
| Todo S et al. | Clinical small bowel or small bowel plus liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721369 |
| Tzakis AG et al. | Use of FK 506 in pediatric patients. | 1991 | Transplant. Proc. | pmid:1703353 |
| Fries D et al. | Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. | 1991 | Transplant. Proc. | pmid:1721370 |
| Jain AB et al. | Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1703354 |
| Wijnen RM et al. | Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. | 1991 | Transplant. Proc. | pmid:1721371 |
| Venkataramanan R et al. | Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1703355 |
| Lopez OL et al. | Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721400 |
| Viebahn R et al. | Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721401 |
| Morrisett JD et al. | Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. | 1991 | Transplant. Proc. | pmid:1721402 |
| Jacobs TW et al. | The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. | 1991 | Transplant. Proc. | pmid:1721403 |
| Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
| Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
| Valdivia LA et al. | Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721432 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Wu GD et al. | FK 506 inhibits the development of transplant arteriosclerosis. | 1991 | Transplant. Proc. | pmid:1721433 |
| Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
| Kobayashi N et al. | Effect of FK 506 on abdominal organ cluster transplantation in pigs. | 1991 | Transplant. Proc. | pmid:1721434 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Nossal GJ | Summary of the First International FK 506 Congress: perspectives and prospects. | 1991 | Transplant. Proc. | pmid:1721464 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Staruch MJ et al. | Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. | 1991 | Int. J. Immunopharmacol. | pmid:1721613 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
| Matsuura T et al. | [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. | 1991 | Hinyokika Kiyo | pmid:1721767 |
| Morris PJ | Cyclosporine, FK-506 and other drugs in organ transplantation. | 1991 | Curr. Opin. Immunol. | pmid:1721824 |
| Takahara S et al. | Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. | 1991 | J Clin Lab Immunol | pmid:1726566 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| James DG | Which immunomodulator? | 1991 | Br J Clin Pract | pmid:1718384 |
| Flavin T et al. | Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. | 1991 | Transplant. Proc. | pmid:1703701 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |
| Jiang H et al. | Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703702 |